Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Tivanisiran (Primary)
- Indications Dry eyes; Ocular pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sylentis
- 14 Mar 2016 Results and additional analysis of this clinical trial will be presented at the ARVO conference in May 2016, according to a Sylentis media release.
- 14 Mar 2016 Results published in a Sylentis media release.
- 22 May 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.